Idexx Laboratories Stock News

17 Capital Partners LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 55.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 630 shares of the companys stock after selling 800 shares during the period. 17 Capital Partners LLCs holdings in []

Related Stocks: IDXX ,

Pensionfund Sabic lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,200 shares of the companys stock after selling 600 shares during the quarter. Pensionfund Sabics holdings in IDEXX Laboratories were worth $2,612,000 []

Maverick Capital Ltd. lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4,470.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,691 shares of the companys stock after purchasing an additional 1,654 shares during the quarter. Maverick Capital []

Sunflower Bank N.A. bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, HoldingsChannel reports. The firm bought 526 shares of the companys stock, valued at approximately $332,000. Other institutional investors also recently made changes to their positions in the company. Meridian Wealth Partners LLC bought a new stake in []

IDEXX' (IDXX) global Reference Lab businesses are robust driven by high same-store volume growth with strong gains across testing categories.

IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q3 2021 Results - Earnings Call Transcript

IDEXX's (IDXX) Q3 top line rides on strong sales at the CAG and Water businesses.

Idexx (IDXX) delivered earnings and revenue surprises of 7.98% and 2.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WESTBROOK, Maine, Oct. 8, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has sc

If you are screening the market for investment opportunities among U.S.-listed equities, you may want to consider the stocks listed below, as they have seen their free cash flow increase notably over